Year: 2011
Type: article
Abstract: Lornoxicam is a NSAID of the oxicam class and it has the same side effects of this groupwhen taken orally. In attempts to avoid the systemic side effects of lornoxicam (e.g. gastricirritation) and to achieve sustained release of the drug, several buccal patch formulationscontaining lornoxicam were prepared using different polymers and were evaluated for in-vitrocharacteristics in part I of this study. In the current study, the selected formulations (based onthe previous in-vitro data) are evaluated for in-vivo performance using experimental animalsand clinical efficacy on human volunteers. Pharmacokinetic parameters were assessedfollowing application of the selected patches in rabbits. A comparative clinical study wasconducted on patients with post-operative pain and edema following maxillofacial operations.The results of the in-vivo animal experiment showed that lornoxicam formulated in differentbuccal patches was successfully delivered to the systemic circulation and showed high absolutebioavailability of lornoxicam. The clinical study results revealed that sodium carboxy methylcellulose (NaCMC, 3%) formulation applied to the buccal mucosa was slightly better or equallyeffective to the orally administered commercial oxicam product (Feldene Flash® tablets) inreducing pain level, swelling and tenderness within a period of 4 days with no observed sideeffects. These findings suggest that lornoxicam administered in this buccal patch may present apotential therapeutic use as a strong anti-inflammatory and analgesic agent.
Authors: Fawzia Habib, Salah Shaltout, Maha Azeem, Gihan Fetih, Mohamed Safwat
Institution: Assiut University
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2993184570